Dengue fever vaccines have undergone significant development, with notable advancements in research and clinical trials. Dengue, caused by the Dengue virus transmitted through Aedes mosquitoes, poses a substantial global health threat, and the pursuit of an effective vaccine has been a priority. Among the prominent candidates is Dengvaxia (CYD-TDV) by Sanofi Pasteur, the first Dengue vaccine licensed in several countries. However, its usage is restricted to individuals with prior Dengue exposure due to concerns about potential increased severity in Dengue-naive individuals. Ongoing research focuses on developing vaccines that provide broad protection across multiple Dengue virus serotypes, addressing the challenges of incomplete immunity and the risk of severe Dengue in certain populations. Several promising candidates are in various stages of clinical evaluation, offering hope for a more widely applicable and efficacious Dengue vaccine in the future. As the field of Dengue vaccine development is dynamic, it is essential to stay informed about the latest advancements and regulatory approvals beyond my last update in January 2022.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States